4 Results for "

TAK-960

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "TAK-960" in MCE Product Catalog:

2
2 Cited Publications
Art. -Nr.: HY-15160
CAS. Nr.: 1137868-52-0
Reinheit:  99.75%
Forschungsgebiete:  

Cancer

TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
loading...
    loading...
2
2 Cited Publications
Art. -Nr.: HY-15160B
Reinheit:  99.19%
Forschungsgebiete:  

Cancer

TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
loading...
    loading...
Art. -Nr.: HY-15160A
CAS. Nr.: 1137868-96-2
Forschungsgebiete:  

Cancer

TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
loading...
    loading...
Art. -Nr.: HY-15160C
CAS. Nr.: 2108449-45-0
Forschungsgebiete:  

Cancer

TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .
loading...
    loading...